In this interview from the ASRS 2013 Annual Meeting, Dr. David Williams discusses positive early results from the MAHALO study, which showed that lampalizumab (anti-factor D) can slow the progression rate of geographic atrophy in patients with dry AMD. This is the first study to show a beneficial treatment effect with a complement inhibitor in geographic atrophy.